## Single-cell RNA sequencing reveals distinct tumor

## microenvironmental patterns in lung adenocarcinoma

Philip Bischoff<sup>1,2</sup>, Alexandra Trinks<sup>1,2</sup>, Benedikt Obermayer<sup>3</sup>, Jan Patrick Pett<sup>3</sup>, Jennifer Wiederspahn<sup>1,4</sup>, Florian Uhlitz<sup>4,5</sup>, Xizi Liang<sup>1</sup>, Annika Lehmann<sup>1</sup>, Philipp Jurmeister<sup>1,2,5</sup>, Aron Elsner<sup>6</sup>, Tomasz Dziodzio<sup>2,6</sup>, Jens-Carsten Rückert<sup>6</sup>, Jens Neudecker<sup>6</sup>, Christine Falk<sup>7,8</sup>, Dieter Beule<sup>3</sup>, Christine Sers<sup>1,2,5</sup>, Markus Morkel<sup>1,2,5</sup>, David Horst<sup>1,2,5</sup>, Nils Blüthgen<sup>1,2,4,5,9</sup>, Frederick Klauschen<sup>1,5,9</sup>

## Affiliations:

- Charité Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Pathology, Charitéplatz 1, 10117 Berlin, Germany
- 2) Berlin Institute of Health at Charité Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany
- Berlin Institute of Health at Charité Universitätsmedizin Berlin, Core Unit Bioinformatics, Charitéplatz 1, 10117 Berlin, Germany
- 4) IRI Life Sciences, Humboldt University of Berlin, Philippstrasse 13, 10115 Berlin, Germany
- 5) German Cancer Consortium (DKTK), Partner Site Berlin, and German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany
- 6) Charité Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Surgery, Campus Charité Mitte and Campus Virchow-Klinikum, Charitéplatz 1, 10117 Berlin, Germany
- 7) Institute of Transplant Immunology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany
- DZIF, German Center for Infectious Diseases, TTU-IICH Hannover-Braunschweig site, 38124 Braunschweig, Germany
- 9) joint last authors

Corresponding author: Philip Bischoff, philip.bischoff@charite.de, +49 30 450 536 127



D









UMAP2

UMAP1

(A) Scatter plots of quality control parameters of all single-cell transcriptomes analyzed in the study, red dashed lines indicate cut-off values for filtering of high-quality transcriptomes. (B) Violin plots of selected quality control parameters grouped by tissue sample, n = normal tissue, t = tumor tissue. (C) UMAPs of epithelial, stromal and immune single-cell transcriptomes, color-coded by patients. In epithelial transcriptomes, clusters predominantly originating from normal tissues are encircled in black. (D) UMAPs of epithelial, stromal and immune single-cell transcriptomes, color-coded by cell doublet assignment using DoubletFinder v2. Clusters 'a' have been removed because of coexpression of the immune marker gene *PTPRC*, cluster 'b' represents normal epithelial cells, cluster 'c' represents normal endothelial cells, cluster 'd' has been removed because of coexpression of the epithelial marker gene *EPCAM*. Taken together, increased numbers of cell doublets were only found in cell clusters, which are not relevant for further analyses of microenvironmental patterns.



H&E staining of lung adenocarcinomas analyzed in the study. For patients P018 and P019, representative tumor tissue shown, for all other patients, consecutive tissue sections of the sample used to prepare single-cell suspensions is shown. Black squares indicate magnified areas. Scale bars indicate 1000 µm or 100 µm in overview or magnified images, respectively.



(A) UMAPs based on the top 20 principal components of all epithelial single-cell transcriptomes split by tissue type, color-coded by cluster, cluster number indicated. (B) Relative size of clusters within normal (blue) or tumor (red) tissue samples. Clusters overrepresented in normal or tumor tissue samples were defined as normal or tumor cell clusters, repectively. (C) Quantification of cell cycle phase of tumor epithelial cells, grouped by patients. (D) Pathway activity scores of selected signaling pathways in *KRAS* wildtype and mutated, or *TP53* wildtype and mutated patients, respectively; n = 10, two-sided Welch's t-test statistics. (E) UMAPs of tumor epithelial cells based on the top 4, 6, or 8 principal components, color-coded by patient, histological subtype, or the score of principal component 1; for patient color code see (F). (F) Distribution of patient origin of tumor epithelial cells sorted along principal component 1. (G) Heatmap of the top 30 genes positively or negatively correlated with principal component 1 which were defined as the "alveolar/club-like" and "undifferentiated" gene signature, respectively, shown for the top 500 cells with the highest or lowest PCA scores, respectively. (H) Mean module scores of the tumor cell signatures based on the top 30 genes positively or negatively correlated with principal component 1 (see (G)), respectively, in tumor epithelial cells sorted along principal component 1. (I) Distribution of cell cycle phase of tumor epithelial cells sorted along principal component 1.



(A) Copy-number aberrations in tumor tissue samples inferred from single-cell transcriptomes using inferCNV. Copy number aberrant clones were cut at k = 4 in inferCNV dendrograms. Clone-wise SCNA scores were computed by calculating the ratio of average standard deviation in inferCNV expression of all cells and all normal samples taken together. Clones with a SCNA score greater than the highest observed score for normal samples were considered copy number aberrant. For p018, p030 and p033, all clones except the one with the lowest SCNA score was considered copy number aberrant. (B) UMAPs of epithelial cells, color-coded by tissue sample type, cluster type, and copy number clone. Cluster type assignment is based on tissue origin and indicates if clusters are overrepresented in normal or tumor tissue samples (see also Supp. Fig. 3A-B). Quantification of epithelial cells, color-coded by cluster type or copy number clone, grouped by tissue sample type.



Α

Cell type gene signatures (Vieira Braga et al. 2019)



#### Cell type gene signatures (Travaglini et al. 2020)

## **Supplemental Figure 5**

(A+B) Mean module scores of cell type gene signatures according to (A) Vieira Braga et al. (doi: 10.1038/s41591-019-0468-5) or (B) Travaglini et al. (doi: 10.1038/s41586-020-2922-4) for manually annotated epithelial, immune and stromal cell clusters.

Α





## **Supplemental Figure 6**

(A) Quantification of endothelial and fibroblastic/muscle cell clusters per patient for normal tissue samples. (B) Differentially expressed genes of endothelial cell clusters, maximum top 10 genes showed per cluster, black arrowheads indicate genes mentioned in the main text.

В





Immune cells



(A-B, D-E) Gene expression and clinical data were obtained from Kim et al. 2020 (doi: 10.1038/s41467-020-16164-1) and preprocessed as our dataset. Single-cell transcriptomes were projected in the UMAP spaces of our dataset and cell type labels were transferred from our dataset using the "ingest" function of the "Scanpy" toolbox. (A-B) Projected UMAPs of all (A) stromal or (B) immune single-cell transriptomes of Kim et al., color-coded by cell cluster; and relative quantification of (A) endothelial and fibroblastic/muscle or (B) myeloid and lymphoid cell clusters per tissue type and patient.

(C-D) Principal component analysis of (C) our cohort or (D) the cohort of Kim et al. based on the proportion of stromal and immune cell clusters, color-coded by (C) histological subtype or (D) histological grade, patients indicated, dotted lines represent separation of patients in two main groups along principal component 1. (E) Normalized proportion of stromal and immune cell clusters and mean module scores of tumor cell signatures in the cohort of Kim et al., histopathological and clinical features indicated per patient (obtained from Kim et al. 2020, Fig. 2d), patients sorted along the first principal component from principal component analysis in (D), cell clusters included in the model in main Fig. 5H in bold. (F) Relative proportion of stromal and immune cell clusters in patient groups in the cohort of Kim et al.; n = 10, two-sided Mann-Whitney U test statistics.



(A) Quantification of myeloid and lymphoid cell clusters per patient for normal tissue samples. (B) Differentially expressed genes of macrophage cell clusters, maximum top 10 genes showed per cluster, black arrowheads indicate genes mentioned in the main text. (C) Differentially expressed genes of T cell clusters, maximum top 10 genes showed per cluster, black arrowheads indicate genes mentioned in the main text. (D) Multiplex immunofluorescence staining of proinflammatory macrophages using CXCL9 and CD68, and tumor cells using CK8, scale bar =  $100 \mu m$ .



(A) Relative proportion of stromal and immune cell clusters in patient groups; n = 10, two-sided Mann-Whitney U test statistics. (B) Correlation of the proportion of immune and stromal cell clusters in tumor tissue samples, cell clusters occurring in less than three tumor tissue samples were excluded from analysis; Spearman's correlation statistics, only correlations with p < 0.05 shown. (C) Correlation of ssGSEA enrichment scores of cell cluster marker gene signatures in the TCGA lung adenocarcinoma cohort; Spearman's correlation statistics, only correlations with p < 0.05 shown.



Heatmap of significant interactions between tumor and microenvironmental cells as computed using the CellPhoneDB algorithm, filtered for interactions where receptors are expressed in tumor cells and ligands are expressed in microenvironmental cells of the N<sup>3</sup>MC or CP<sup>2</sup>E pattern, and filtered for high-confidence canonical receptors and ligands of relevant oncogenic pathways (see Supp. Table 6), color-coded by p-value.



(A-C) Kaplan-Meier overall survival curves of 524 cases from the TCGA lung adenocarcinoma cohort. (A) Cases were grouped by ssGSEA enrichment scores of marker gene sets of epithelial, immune and stromal cell subtypes which are characteristic for the N<sup>3</sup>MC and CP<sup>2</sup>E tumor microenvironmental patterns, for marker gene sets see Supp. Tables 7-10. (B) All marker genes or the top 5 marker genes per cell subtype of the N<sup>3</sup>MC and CP<sup>2</sup>E pattern (see (A)) were combined, respectively, and TCGA cases were grouped by the ratio of ssGSEA enrichment scores of the combined N<sup>3</sup>MC and CP<sup>2</sup>E gene sets. (C) All marker genes or the top 5 marker genes of myofibroblast cl. 1 and monocyte-derived macrophages cl. 1 (N<sup>3</sup>MC pattern, see (A)) or undifferentiated tumor cells and myofibroblast cl. 2 (CP<sup>2</sup>E pattern, see (A)) were combined, respectively, and TCGA cases were grouped by the ratio of ssGSEA enrichment Scores of the simplified combined N<sup>3</sup>MC and CP<sup>2</sup>E gene sets. (A-C) "high" indicates ssGSEA enrichment score > median, "low" indicates ssGSEA enrichment score < median, n = 524, log-rank statistics. (B-C) For complete and simplified short combined gene sets, see Supp. Table 11.